Eyepoint Pharmaceuticals Inc (EYPT) Stock Price, Quote & News

Company Profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Duras...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 926 5000

Website: eyepoint.bio

Address:

480 Pleasant Street, Suite C-400, Watertown, United States

KimboIce Jun. 24 at 9:43 PM

$EYPT pure consolidation today on the down low

0 · Reply

rizzato Jun. 24 at 6:59 PM

$EYPT DROPPPPPPPPPPPPPP

0 · Reply

Tmoney85285 Jun. 24 at 3:13 PM

$OCUL y'all had your chance to get out in the mid 10's. you would've looked dare i say, smart? shorts own this one- and if you're looking to $EYPT to save you, that's equally as pathetic.

0 · Reply

KimboIce Jun. 24 at 2:24 PM

$OCUL $EYPT you are at break even . Quit while you can . There are far less risky shorts out there . If EYPT Lugano results are positive, I can see Ocul go up 30-50% on the news. MM’s are long-term strategic thinkers . They are not nubes tracking the daily . The market sees two companies = 2X resources fasts tracks new SOC . It’s ironic that management teams hate each other and need each other at the same time .

1 · Reply

twib Jun. 23 at 4:55 PM

$EYPT solid day! Movin on up, one of these times itll stay up.

1 · Reply

Goodstockday Jun. 22 at 2:57 PM

$OCUL $EYPT The Durability Label Differences are a game changer. See this post from @AscendingBio https://x.com/AscendingBio/status/2069058177543315941

1 · Reply

Quantumup Jun. 22 at 1:49 PM

H.C. Wainwright (a/o 6/18)⬆️ $OCUL-$25,⬆️PoS & reit'd Buy after Ocular hosted its Investor Day in NYC, in which the company discussed the outcome of its Type C meeting with the FDA and the KOLs endorsed the adoption of AXPAXLI. $EYPT SRZN REGN $FDMT RHHBY KOD Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2069054846682931637?s=20

0 · Reply

Darth_Barrister Jun. 20 at 10:50 PM

$EYPT Sticking my toe in for the next readout. Any history or other data points to inform the odds of a “Mid-2026” readout before July 17 expiration? TIA.

0 · Reply

rizzato Jun. 19 at 8:01 AM

$EYPT still no news about the update short interest

1 · Reply

Goodstockday Jun. 18 at 6:00 PM

$EYPT Have they said anything about what kind of a duration they are seeking on the label. The phase 3 appears to redose at 24 weeks. Is that likely to be on the label as the max? Do they have other data that might be able to extend that?

1 · Reply

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 9, 2026, 11:20 AM EDT - 16 days ago

EyePoint Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 4:55 PM EDT - 22 days ago

EyePoint Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 9:00 AM EDT - 4 weeks ago

EyePoint Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 19, 2026, 7:00 AM EDT - 5 weeks ago

EyePoint Announces Participation at Upcoming Investor Conferences

2026-05-14T14:31:25.000Z - 6 weeks ago

EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials

May 14, 2026, 9:51 AM EDT - 6 weeks ago

EyePoint's late-stage eye drug trials to continue after safety panel review

May 14, 2026, 7:00 AM EDT - 6 weeks ago

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

2026-05-07T07:35:29.000Z - 7 weeks ago

EyePoint reports Q1 EPS (99c), consensus (81c)

May 6, 2026, 8:30 AM EDT - 7 weeks ago

EyePoint Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 7 weeks ago

EyePoint Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 7 weeks ago

EyePoint Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 7 weeks ago

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Apr 29, 2026, 7:00 AM EDT - 2 months ago

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

Apr 27, 2026, 8:00 AM EDT - 2 months ago

EyePoint Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

EyePoint Proxy statement: Proxy filing

Apr 23, 2026, 7:00 AM EDT - 2 months ago

EyePoint Slides: Corporate presentation

Mar 25, 2026, 8:45 AM EDT - 3 months ago

EyePoint Transcript: RBC Capital Markets Virtual Ophthalmology Conference

Mar 20, 2026, 5:24 PM EDT - 3 months ago

EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

OCUL

2026-03-09T10:55:47.000Z - 3 months ago

EyePoint price target raised to $35 from $31 at Citi

2026-03-05T11:11:09.000Z - 4 months ago

EyePoint price target raised to $30 from $23 at H.C. Wainwright

2026-03-04T19:55:31.000Z - 4 months ago

EyePoint price target raised to $29 from $27 at Chardan

Mar 4, 2026, 8:30 AM EST - 4 months ago

EyePoint Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

EyePoint Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 4 months ago

EyePoint Earnings release: Q4 2025

2026-03-04T12:10:17.000Z - 4 months ago

EyePoint reports Q4 EPS (81c), consensus (75c)

2026-03-04T12:09:56.000Z - 4 months ago

EyePoint expects cash to fund operations into Q4 2027

Mar 4, 2026, 7:00 AM EST - 4 months ago

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

Mar 3, 2026, 2:30 PM EST - 4 months ago

EyePoint Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T12:22:21.000Z - 4 months ago

EyePoint announces first patients dosed in Global Phase 3 trials of DURAVYU

Mar 2, 2026, 7:00 AM EST - 4 months ago

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

Mar 2, 2026, 7:00 AM EST - 4 months ago

EyePoint Slides: Investor presentation

Feb 25, 2026, 7:00 AM EST - 4 months ago

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

2026-02-19T12:28:49.000Z - 4 months ago

EyePoint price target raised to $36 from $33 at Mizuho

2026-02-18T12:05:24.000Z - 4 months ago

EyePoint appoints Campbell as Chief Commercial Officer

Feb 18, 2026, 7:00 AM EST - 4 months ago

EyePoint Appoints Michael Campbell as Chief Commercial Officer

Feb 12, 2026, 11:00 AM EST - 4 months ago

EyePoint Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 5 months ago

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 13, 2026, 10:30 AM EST - 5 months ago

EyePoint Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 10:30 AM EST - 5 months ago

EyePoint Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 5 months ago

EyePoint Slides: Investor presentation

2026-01-07T12:05:19.000Z - 6 months ago

EyePoint reports corporate update, 2026 anticipated milestones for DURAVYU

Jan 7, 2026, 7:00 AM EST - 6 months ago

EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026

Dec 17, 2025, 7:00 AM EST - 6 months ago

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-09T16:15:28.000Z - 7 months ago

Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’

OCUL

2025-11-19T12:05:09.000Z - 7 months ago

EyePoint announces DSMC completed review of Phase 3 trial for DURAVYU

Nov 19, 2025, 7:00 AM EST - 7 months ago

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Nov 12, 2025, 10:40 AM EST - 8 months ago

EyePoint Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:40 AM EST - 8 months ago

EyePoint Slides: FY 2025

2025-11-11T12:20:18.000Z - 8 months ago

EyePoint selloff brings buying opportunity, says Mizuho

Nov 10, 2025, 10:30 AM EST - 8 months ago

EyePoint Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 8:30 AM EST - 8 months ago

EyePoint Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

EyePoint Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

EyePoint Earnings release: Q3 2025

2025-11-05T12:11:53.000Z - 8 months ago

EyePoint reports Q3 EPS (85c), consensus (77c)

Nov 5, 2025, 7:00 AM EST - 8 months ago

EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Oct 29, 2025, 7:00 AM EDT - 8 months ago

EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 14, 2025, 10:43 PM EDT - 9 months ago

EyePoint Announces Pricing of Public Offering

Oct 14, 2025, 4:35 PM EDT - 9 months ago

EyePoint Announces Proposed Public Offering of Common Stock

Oct 14, 2025, 4:01 PM EDT - 9 months ago

EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema

Sep 3, 2025, 2:45 PM EDT - 10 months ago

EyePoint Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 2:30 PM EDT - 10 months ago

EyePoint Transcript: Citi's Biopharma Back to School Conference

Aug 13, 2025, 10:00 AM EDT - 11 months ago

EyePoint Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 8:30 AM EDT - 11 months ago

EyePoint Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

EyePoint Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

EyePoint Earnings release: Q2 2025

Aug 6, 2025, 7:30 AM EDT - 11 months ago

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 6, 2025, 7:00 AM EDT - 11 months ago

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Jul 30, 2025, 7:00 AM EDT - 11 months ago

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 29, 2025, 7:00 AM EDT - 11 months ago

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Jun 10, 2025, 2:40 PM EDT - 1 year ago

EyePoint Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 2:40 PM EDT - 1 year ago

EyePoint Slides: Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025, 8:30 AM EDT - 1 year ago

EyePoint Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration

May 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint Slides: Investor Presentation

May 20, 2025, 10:00 AM EDT - 1 year ago

EyePoint Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 16, 2025, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 9, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings Call Transcript: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Quarterly report: Q1 2025

May 7, 2025, 8:30 AM EDT - 1 year ago

EyePoint Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

Apr 30, 2025, 7:00 AM EDT - 1 year ago

EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

EyePoint Proxy statement: Proxy Filing

Apr 4, 2025, 10:00 AM EDT - 1 year ago

EyePoint Transcript: RBC Inaugural Virtual Ophthalmology Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 12, 2025, 3:00 PM EDT - 1 year ago

EyePoint Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 4:20 PM EDT - 1 year ago

EyePoint Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

EyePoint Earnings release: Q4 2024

Mar 5, 2025, 7:00 AM EST - 1 year ago

EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments

Mar 4, 2025, 9:10 AM EST - 1 year ago

EyePoint Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 9:10 AM EST - 1 year ago

EyePoint Slides: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025

Feb 25, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference

Feb 6, 2025, 9:30 AM EST - 1 year ago

EyePoint Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Transcript: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Press release: Status Update

Feb 5, 2025, 8:00 AM EST - 1 year ago

EyePoint Slides: Status Update

Jan 30, 2025, 7:00 AM EST - 1 year ago

EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Jan 14, 2025, 5:15 PM EST - 1 year ago

EyePoint Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 5:15 PM EST - 1 year ago

EyePoint Slides: FY 2025

Jan 8, 2025, 7:00 AM EST - 1 year ago

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.

Dec 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

Nov 19, 2024, 3:00 AM EST - 1 year ago

EyePoint Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 4:15 PM EST - 1 year ago

EyePoint Transcript: UBS Global Healthcare Conference 2024

Nov 11, 2024, 2:00 PM EST - 1 year ago

EyePoint Transcript: Guggenheim's Inaugural Healthcare Innovation Conference

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

EyePoint Earnings release: Q3 2024

Nov 4, 2024, 7:00 AM EST - 1 year ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Oct 31, 2024, 4:00 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

Oct 29, 2024, 9:47 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Oct 28, 2024, 5:14 PM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

Oct 24, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

Oct 2, 2024, 2:30 PM EDT - 1 year ago

EyePoint Transcript: UBS Virtual Ophthalmology Day

Sep 18, 2024, 11:30 AM EDT - 1 year ago

EyePoint Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 4:20 PM EDT - 1 year ago

EyePoint Transcript: The Baird 2024 Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Aug 15, 2024, 7:00 AM EDT - 2 years ago

EyePoint Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 8:00 AM EDT - 2 years ago

EyePoint Registration statement: Registration Filing

Aug 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 7, 2024, 7:15 AM EDT - 2 years ago

EyePoint Quarterly report: Q2 2024

Aug 7, 2024, 7:15 AM EDT - 2 years ago

EyePoint Earnings release: Q2 2024

Jul 9, 2024, 6:00 AM EDT - 2 years ago

EyePoint Slides: Investor Presentation

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Transcript: R&D Day 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Press release: FY 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Slides: FY 2024

Jun 18, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Jun 12, 2024, 3:20 PM EDT - 2 years ago

EyePoint Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 12, 2024, 3:20 PM EDT - 2 years ago

EyePoint Slides: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

May 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

EyePoint Earnings release: Q1 2024

May 6, 2024, 9:10 AM EDT - 2 years ago

EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal

May 6, 2024, 8:00 AM EDT - 2 years ago

EyePoint Transcript: Study Update

May 6, 2024, 8:00 AM EDT - 2 years ago

EyePoint Press release: Study Update

May 6, 2024, 8:00 AM EDT - 2 years ago

EyePoint Slides: Study Update

May 6, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

Apr 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

EyePoint Proxy statement: Proxy Filing

Apr 2, 2024, 7:00 AM EDT - 2 years ago

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Mar 13, 2024, 9:15 AM EDT - 2 years ago

EyePoint Transcript: Guggenheim 5th Annual Healthy Altitudes Summit

Mar 7, 2024, 8:30 AM EST - 2 years ago

EyePoint Earnings Call Transcript: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

EyePoint Annual report: Q4 2023

Mar 7, 2024, 8:30 AM EST - 2 years ago

EyePoint Earnings release: Q4 2023

Mar 7, 2024, 7:00 AM EST - 2 years ago

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

KimboIce Jun. 24 at 9:43 PM

$EYPT pure consolidation today on the down low

0 · Reply

rizzato Jun. 24 at 6:59 PM

$EYPT DROPPPPPPPPPPPPPP

0 · Reply

Tmoney85285 Jun. 24 at 3:13 PM

$OCUL y'all had your chance to get out in the mid 10's. you would've looked dare i say, smart? shorts own this one- and if you're looking to $EYPT to save you, that's equally as pathetic.

0 · Reply

KimboIce Jun. 24 at 2:24 PM

1 · Reply

twib Jun. 23 at 4:55 PM

$EYPT solid day! Movin on up, one of these times itll stay up.

1 · Reply

Goodstockday Jun. 22 at 2:57 PM

$OCUL $EYPT The Durability Label Differences are a game changer. See this post from @AscendingBio https://x.com/AscendingBio/status/2069058177543315941

1 · Reply

Quantumup Jun. 22 at 1:49 PM

0 · Reply

Darth_Barrister Jun. 20 at 10:50 PM

$EYPT Sticking my toe in for the next readout. Any history or other data points to inform the odds of a “Mid-2026” readout before July 17 expiration? TIA.

0 · Reply

rizzato Jun. 19 at 8:01 AM

$EYPT still no news about the update short interest

1 · Reply

Goodstockday Jun. 18 at 6:00 PM

1 · Reply

Goodstockday Jun. 17 at 8:38 PM

$EYPT The $OCUL presentation today was really strong. It is always important to stay educated on the competition. If you are an $EGYT investor, it is an essential listen.

1 · Reply

KimboIce Jun. 17 at 2:00 PM

$OCUL $EYPT Good derisking news for Ocul. SP heavily manipulated. Your next catalyst is Lugano results in August . They also don’t need efficacy data on SOL-R , which is a huge advantage to getting approval. If Lugano results positive, it should lift Ocul to 13-14 range again because it further derisks sustained TKI market. Not a zero sum game. We are attached at the hip whether you like it or not .

1 · Reply

rizzato Jun. 15 at 8:03 PM

$EYPT hopefully will arrive the day when you f……. Shorters will see the really value of that company and will buy a lot of Vaseline

1 · Reply

rizzato Jun. 15 at 7:34 PM

$EYPT low volume shorters on a party No way to go up

0 · Reply

Tom2772 Jun. 13 at 5:46 AM

$OTLK $EYPT $APLS What a strong week for $OTLK 🚀🔥 "The Office of New Drugs (OND) concluded that substantial evidence of effectiveness has been established and that additional adequate and well-controlled clinical studies are not required for approval of ONS-5010." EU approval ✅UK approval ✅Commercial launch underway in Germany and the UK ✅FDA appeal confirmed efficacy ✅BLA resubmission announced June 1st and accepted as a Class 1 review (~60 days) ✅Final FDA decision pending ⏳ Connect the dots. The picture is getting pretty clear. 👀🚀 This story keeps getting stronger.💪

1 · Reply

KimboIce Jun. 12 at 2:13 PM

$EYPT

0 · Reply

MaxKlim Jun. 11 at 2:44 AM

$EYPT $OCUL did you read RJ today??? Ha ha ha

1 · Reply

rizzato Jun. 10 at 9:57 PM

$EYPT not bad at all

0 · Reply

rizzato Jun. 10 at 9:46 PM

$EYPT https://www.investing.com/news/transcripts/eyepoint-at-goldman-sachs-healthcare-conference-sustainedrelease-vision-93CH-4089882

0 · Reply

MaxKlim Jun. 9 at 12:57 PM

$EYPT $OCUL Why listen to those who don't even come close? Like that sore loser filing for a restraining order that’s bound to be rejected? You’d be better off listening to the speech by the leader of this race.

1 · Reply

KimboIce Jun. 9 at 12:51 PM

$OCUL you guys gotta get out of the echo chamber and actually listen to your competition’s call instead of pulling quotes with no context . Duker is referring to statistical superiority in treatment burden . Not statistical superiority in BCVA . They have always been consistent when referencing this secondary endpoint. $EYPT look forward to Goldman Sachs presentation today . You guys should listen with an objective mindset.

3 · Reply

Poet5 Jun. 6 at 5:28 PM

$EYPT Anyone who does not by at 11.25 and under is a complete moron!

0 · Reply

Market Cap	1.47B
Revenue (ttm)	43.27M
Net Income (ttm)	-130.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-302.45%
Debt to Equity Ratio	0.00

Volume	1,429,818
Avg Vol	1,347,702
Day's Range	N/A - N/A
Shares Out	82.79M
Stochastic %K	98%
Beta	1.67
Analysts	Strong Sell
Price Target	$34.00